Combined renin-angiotensin-aldosterone system inhibition in patients with chronic heart failure secondary to left ventricular systolic dysfunction

American Heart Journal

Volumn 157, Issue 6 SUPPL., 2009, Pages

  Gradman, Alan H ^a,b   Papademetriou, Vasilios ^c  

^a WESTERN PENNSYLVANIA HOSPITAL   (United States)

^b TEMPLE UNIVERSITY   (United States)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; LISINOPRIL; PLACEBO; RAMIPRIL; SPIRONOLACTONE; TELMISARTAN; TRANDOLAPRIL; VALSARTAN;

ACUTE HEART INFARCTION; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL STUDY; CLINICAL TRIAL; DEATH; DISEASE COURSE; ECONOMICS; HEALTH CARE COST; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; INCIDENCE; MONOTHERAPY; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT OUTCOME; UNITED STATES;

AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE, SYSTOLIC; HUMANS; MALE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 65549108889     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2009.04.007     Document Type: Article

References (27)

1. American Heart Association/American Stroke Association. Heart disease and stroke statistics: 2007 update at-a-glance. Dallas, Texas. Available at (2007). http://www.americanheart.org/downloadable/heart/1166712318459HS_StatsIns ideText.pdf Last accessed July 3, 2008
2. Roger V.L., Weston S.A., Redfield M.M., et al. Trends in heart failure incidence and survival in a community-based population. JAMA 292 (2004) 344-350
3. O'Connell J.B., and Bristow M.R. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant 13 (1994) S107-S112
4. Gibbs C.R., Davies M.K., and Lip G.Y. ABC of heart failure. Management: digoxin and other inotropes, beta blockers, and antiarrhythmic and antithrombotic treatment. BMJ 320 (2000) 495-498
5. Delgado III R.M., and Willerson J.T. Pathophysiology of heart failure: a look at the future. Tex Heart Inst J 26 (1999) 28-33
6. Gheorghiade M., and Bonow R.O. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation 97 (1998) 282-289
7. Willerson J.T. Other cardiomyopathies. In: Willerson J.T., and Cohn J.N. (Eds). Cardiovascular medicine (1995), Churchill Livingstone, New York 888-894
8. Cohn J.N. Overview of pathophysiology of clinical heart failure. In: Hosenpud J.D., and Greenberg B.H. (Eds). Congestive heart failure: pathophysiology, diagnosis, and comprehensive approach to management (1994), Springer-Verlag, New York 11-16
9. Jackson G., Gibbs C.R., Davies M.K., et al. ABC of heart failure. Pathophysiology. BMJ 320 (2000) 167-170
10. In: Willerson J.T., and Cohn J.N. (Eds). Cardiovascular medicine (1995), Churchill Livingstone, New York 952-953
11. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316 (1987) 1429-1435
12. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991) 293-302
13. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342 (1993) 821-828
14. Køber L., Torp-Pedersen C., Carlsen J.E., et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 333 (1995) 1670-1676
15. Greenberg B., Quinones M.A., Koilpillai C., et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation 91 (1995) 2573-2581
16. Hunt S.A., American College of Cardiology, and American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 46 (2005) e1-e82
17. Cohn J.N., Tognoni G., and Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (2001) 1667-1675
18. Pfeffer M.A., Swedberg K., Granger C.B., et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362 (2003) 759-766
19. Granger C.B., McMurray J.J., Yusuf S., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362 (2003) 772-776
20. Young J.B., Dunlap M.E., Pfeffer M.A., et al. Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 110 (2004) 2618-2626
21. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 (1999) 709-717
22. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321 [Erratum in: N Engl J Med 2003;348:2271]
23. McKelvie R.S., Yusuf S., Pericak D., et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation 100 (1999) 1056-1064
24. McMurray J.J., Ostergren J., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362 (2003) 767-771
25. Pfeffer M.A., McMurray J.J., Velazquez E.J., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 (2003) 1893-1906
26. Packer M., Poole-Wilson P.A., Armstrong P.W., et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 100 (1999) 2312-2318
27. Yusuf S., Teo K.K., Pogue J., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 (2008) 1547-1559